GWLLOTCFood and Kindred ProductsFiscal year ends December 31
GOLDENWELL BIOTECH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.65+0.05 (+8.33%)
Close on Oct 19, 2026
- Market cap
- $64.35M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.4500 (+225.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
GOLDENWELL BIOTECH, INC. reported revenue of $55 for the twelve months to Jun 30, 2026.
Revenue
$55
TTM Q2 2026
Operating income
-$114.80K
TTM Q2 2026
EPS, diluted
$0.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $64.35M
- P/E ratio
- –
- Price to sales
- 1170000.00
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $55
- Net income
- -$282.12K
- EPS, diluted
- $0.00
- Book value per share
- -$0.00
- Diluted shares
- 99M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$55
Gross profit
$12
Operating income
-$114.80K
Net income
-$282.12K
EPS, diluted
$0.00
Reported periodTrailing twelve months